MAT: Medications For Addiction Treatment 8 Hour Waiver Training-2021

4.85 (291 votes)

Recorded On: 11/07/2019

  • Register
    • Non-member - Free!
    • Regular Member - Free!
    • Retired Member - Free!
    • Affiliate Member - Free!
    • Student Member - Free!

image

If you have already registered for this course, please DO NOT RE-REGISTER. If you do, your completed work will be erased in the system. Instead please email MAT@apna.org for assistance accessing your training.

For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.* 

In accordance with 2021 changes in practice guidelines for administering buprenorphine for the treatment of opioid use disorder, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine. To treat more than 30 patients, however, providers must complete 24 hours of specialized training to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. The training includes 8 hours of waiver training and an additional 16 hours of training.

Note: This course will expire 90 days from the date of registration. Please complete the course within that time frame or you may have to begin the program again.

Course Description: 

This course is jointly provided by Providers Clinical Support System (PCSS) and American Psychiatric Nurses Association (APNA). The course consists of 8 individual modules (sessions) which are part of the required 24 hours of content for nurses who wish to offer medication assisted treatments for substance use disorders, including buprenorphine. Each module includes a webinar and an evaluation. Some modules will contain a case study component. The final course module contain a final course post-test, overall course evaluation, and your certification of completion. Three attempts are allowed to successfully pass the course post-test. There is a final course evaluation and your certification of course completion. This course needs to be completed within 90 days from your registration date. If you have questions, please email MAT@apna.org.

Target Audience: APRN

Learning Outcomes:
Upon completion of the course, learners will be able to:

  1. Review addiction identification and evidence-based treatments.
  2. Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
  3. Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
  4. Explain the process of buprenorphine induction as well as stabilization and maintenance.
  5. Discuss other approved antagonist and agonist medications to treat OUD.
  6. Discuss basic office protocols including medical record documentation and confidentially.
  7. Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD. 
  8. Apply for a MAT waiver to begin treating patients with OUD.

Nursing Continuing Professional Development:
8.0 contact hours (of which 8.0 are in pharmacology).*In order to receive contact hours for the program, participants must: View the program in its entirety (modules 1-8), earn a passing score of at least 80% on the final course post-test, complete evaluations of each module, the honor statement and the final course evaluation during the allotted 90-day access period. Participants will have three (3) opportunities to correctly answer the questions on the final post-test. If you exceed your three attempts, please contact MAT@APNA.org for assistance. If, after speaking with an APNA nurse educator, you are unable to pass the course post-test on the 4th attempt, you will be required to re-start the course from the beginning in order to ensure full understanding of the content. Following completion of the course modules, post-test, honor statement and evaluations, your nursing continuing professional development certificate will be generated online and available for immediate printing. Credit cannot be earned unless all components of the program are completed. No partial credit can be awarded.

Pricing: Free

Key  Words: Addictions, MAT Training, Substance Use Disorders

Register:  

  • The course is free of charge and can be accessed by clicking the Register button above. You will be prompted to login with your APNA account. If you do not have an APNA account, select the button, "create an account" and complete the listed information to create a free non-member profile. 
  • After completing the 8 hour and 16 hour waiver training, please return to the PCSS website for information on continuing the waiver process, which is outlined in the infographic below. Instructions for obtaining your DEA waiver are provided at the PCSS website. 
  • Click here for the "Steps to Obtain Your MAT Waiver" process map.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Accreditation of this nursing continuing professional development educational activity does not imply endorsement by APNA or ANCC of any commercial products discussed in the context of this activity. 


Funding Statement:  
Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Disclosures:

  • The APNA nurse planner and members of the APNA planning committee have no financial relationships or conflict of interest to disclose. Dr. Wright and Dr. Wyatt have no conflict of interest to disclose. This educational activity may contain discussion of off-label usage of drugs that are not indicated by the FDA. The APNA and the American Academy of Addiction Psychiatry (AAAP) do not recommend usage of any agent outside the FDA approved/labeled indications.


Release Date: March 16, 2020
The contact hours for this session expire: March 31, 2023

*Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.


Components visible upon registration.